Hemant Surgical Industries Ltd
Incorporated in 1989, Hemant Surgical Industries Ltd is in the business of Medical Equipment & Supplies[1]
- Market Cap ₹ 542 Cr.
- Current Price ₹ 373
- High / Low ₹ 446 / 91.0
- Stock P/E 29.8
- Book Value ₹ 106
- Dividend Yield 0.00 %
- ROCE 19.6 %
- ROE 18.1 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 43.0 days to 24.4 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -6.07%
- Debtor days have increased from 87.9 to 106 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 107 | 232 | |
| 98 | 209 | |
| Operating Profit | 9 | 23 |
| OPM % | 9% | 10% |
| 5 | 6 | |
| Interest | 2 | 4 |
| Depreciation | 1 | 2 |
| Profit before tax | 10 | 24 |
| Tax % | 23% | 23% |
| 8 | 18 | |
| EPS in Rs | 7.70 | 13.95 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 117% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 130% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 23% |
| 1 Year: | 306% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 10 | 13 |
| Reserves | 53 | 125 |
| 31 | 50 | |
| 54 | 87 | |
| Total Liabilities | 148 | 274 |
| 40 | 53 | |
| CWIP | 12 | 0 |
| Investments | 1 | 0 |
| 95 | 221 | |
| Total Assets | 148 | 274 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 9 | -32 | |
| -30 | -3 | |
| 18 | 69 | |
| Net Cash Flow | -4 | 34 |
| Free Cash Flow | -26 | -34 |
| CFO/OP | 118% | -119% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 70 | 106 |
| Inventory Days | 208 | 121 |
| Days Payable | 188 | 146 |
| Cash Conversion Cycle | 90 | 81 |
| Working Capital Days | 62 | 24 |
| ROCE % | 20% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Number of Registered Medical Products Count ・Standalone data |
|
|||||
| Gross Cash Cycle (GCA Days) Days ・Standalone data |
||||||
| Manufacturing Infrastructure Footprint Sq. Ft. ・Standalone data |
||||||
| Number of Distributors in India Count ・Standalone data |
||||||
Extracted by Screener AI
Documents
Announcements
-
Revised Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015-Execution Of Semi Knocked Down (SKD) Manufacturing Agreement With Sonomed Escalon, USA
9 Jun - Hemant Surgical revised disclosure on SKD manufacturing agreement with Sonomed Escalon, USA, for two ophthalmic models.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9 Jun - Hemant Surgical acquired 66.66% of Lifesenz Cancer Research Labs for Rs. 19.98 crore, effective June 1, 2026.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
1 Jun - Hemant Surgical completed acquisition of Lifesenz Cancer Research Labs on June 1, 2026; it became a subsidiary.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Hemant Surgical says FY2025-26 Annual Secretarial Compliance Report is not applicable under SME exemption.
-
Announcement under Regulation 30 (LODR)-Acquisition
27 May - Hemant Surgical to acquire 66.66% of Lifesenz for Rs 19.998 crore by September 30, 2026.
Business Overview:[1][2]
HSIL is ISO 9001:2015, ISO 13485:2016 certified and CDSCO compliant company which deals in importing, manufacturing, and marketing medical disposable, surgical equipments and pharmaceutical products including
a) Supply of dialysis equipment, renal care, oxygen concentrators, air mattresses, ultrasound machines and digital thermometers, etc.
b) Design and manufacture of a range of nebulisers, which are
marketed under the company’s AERO brand
c) HSIL also refurbishes second-hand dialysis machines, manufactures
and supplies related accessories, dialysers and haemodialysis solutions